- Home
- JANX
as 11-21-2024 4:00pm EST
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to treat patients suffering from cancer.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 2.9B | IPO Year: | 2021 |
| Target Price: | $65.10 | AVG Volume (30 days): | 637.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.19 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.79 - $65.60 | Next Earning Date: | 11-06-2024 |
| Revenue: | $13,049,000 | Revenue Growth: | 54.12% |
| Revenue Growth (this year): | 66.3% | Revenue Growth (next year): | -48.24% |
Stock Insider Trading Activity of Janux Therapeutics Inc. (JANX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | JANX | Director10% Owner | Oct 18 '24 | Buy | $44.75 | 1,200,000 | $53,700,000.00 | 9,317,246 | |
| Avalon Ventures XI, L.P. | JANX | 10% Owner | Oct 16 '24 | Sell | $49.44 | 1,673,128 | $77,472,371.23 | 401,321 | |
| DiRaimondo Thomas | JANX | Chief Scientific Officer | Sep 27 '24 | Sell | $46.72 | 5,000 | $231,716.19 | 97,938 | |
| Meyer Andrew Hollman | JANX | Chief Business Officer | Sep 27 '24 | Sell | $45.96 | 50,000 | $2,297,755.00 | 67,592 | |
| Campbell David Alan | JANX | President and CEO | Sep 27 '24 | Sell | $46.93 | 25,000 | $1,157,641.43 | 307,054 | |
| Avalon Ventures XI, L.P. | JANX | 10% Owner | Sep 26 '24 | Sell | $47.04 | 307,779 | $14,452,393.76 | 401,321 | |
| Lichter Jay | JANX | 10% Owner | Sep 13 '24 | Sell | $46.68 | 3,815 | $178,084.20 | 7,000 | |
| Avalon Ventures XI, L.P. | JANX | 10% Owner | Sep 10 '24 | Sell | $46.60 | 451,091 | $21,153,619.49 | 401,321 | |
| Avalon Ventures XI, L.P. | JANX | 10% Owner | Sep 6 '24 | Sell | $42.08 | 242,182 | $10,172,364.06 | 401,321 |
Latest Janux Therapeutics Inc. News
JANX Breaking Stock News: Dive into JANX Ticker-Specific Updates for Smart Investing
Barrons.com
6 days ago
Bitdeer Technologies, PBF Energy, and More Stocks See Action From Activist Investors
Simply Wall St.
14 days ago
Janux Therapeutics Third Quarter 2024 Earnings: Misses Expectations
MT Newswires
14 days ago
Wedbush Adjusts Janux Therapeutics Price Target to $75 From $74, Maintains Outperform Rating
Business Wire
15 days ago
Janux Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
Barrons.com
20 days ago
Bath & Body Works, Paramount Global, and More Stocks See Action From Activist Investors
MT Newswires
a month ago
UBS Initiates Janux Therapeutics With Buy Rating, $69 Price Target
GuruFocus.com
a month ago
Paradigm Biocapital Advisors LP Acquires Shares in Janux Therapeutics Inc
GuruFocus.com
a month ago
RA Capital Management Reduces Stake in Janux Therapeutics
Compare JANX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "JANX Janux Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.